Latest Als News

Battery Age Minerals has initiated a comprehensive tailings sampling campaign at its Bleiberg-Hochobir project in Austria to assess germanium concentrations, aiming to secure a critical semiconductor material amid global supply constraints.

Magmatic Resources reports promising drilling results at the Calais prospect within its Myall Project JV with Fortescue, hinting at a significant new copper-gold porphyry discovery. Further drilling is planned to refine the geological model and explore the system’s potential.

Western Yilgarn NL has secured the Cardea 3 Bauxite Project in Western Australia's Darling Range, adding a significant high-grade bauxite asset near its Julimar Project. Historical drilling confirms strong alumina grades and strategic infrastructure access.

Estrella Resources has intersected 6.45 meters of massive manganese oxides in its first-ever drillhole in Timor-Leste, confirming the region’s untapped mineral potential and setting the stage for an extensive follow-up drilling campaign.

ALS Limited has launched a Share Purchase Plan allowing eligible shareholders to invest up to A$30,000 in new shares at a discounted price, following a recent $350 million institutional placement.

ALS Limited has completed a significant institutional placement, issuing over 20.9 million shares at A$16.70 each, bolstering its capital base without the need for full disclosure under the Corporations Act.

Bayan Mining and Minerals has kicked off the second phase of exploration at its Bayan Springs Project in Nevada, building on strong initial gold assay results that hint at significant Carlin-style mineralisation potential.

ALS Limited has successfully completed a $350 million institutional placement, issuing 21 million new shares to fund key laboratory upgrades and maintain financial flexibility. The company also launched a $40 million share purchase plan to further support its growth ambitions.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited has announced an ordinary dividend of AUD 0.197 per share for the half-year ending March 2025, payable in July with flexible currency options for shareholders worldwide.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.